Iovance Biotherapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Going to get started. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today, and it's my pleasure to have the Iovance team. To my direct right, Corleen Roche, CFO, and to her right, Dan Kirby, Chief Commercial Officer. To Dan's right is Brian Gastman, Executive VP Translational Medicine. Is that the right Correct.
Okay. To the right of Brian is Noah Berkowitz, Chief Medical Officer. Welcome, all of you. Maybe just to get started, you've launched a novel TIL therapy, AMTAGVI. It's almost been three years since the initial approval in February of 2024. Maybe talk us through where are we in the launch right now, and looking ahead, you're broadening the pipeline with this product. What catalysts can we look forward to over the next 12 months? That would be helpful. Absolutely.
Thank you, Andrew, and thanks for having us. If we look at where we just finished the third quarter, we did about $122 million in sales in the U.S. for AMTAGVI and PROLEUKIN. In context, we did $264 million all of 2025. When you think about that, the growth has been very strong, especially this year with AMTAGVI. It's a one-time cell therapy in solid tumor, and we've been able to establish a platform of not only treatment centers and surgical oncologists, but also medical oncologists referring those in, that is sustainable and continues to grow. If you look at where we're excited about going forward is opening more ATCs, seeing that growth continue through Q4 into 2027 and beyond. Our focus is to maximize the opportunity in melanoma in the U.S., second line plus metastatic melanoma, getting more approvals.
We're approved right now in the U.S., Canada, and Australia. We have approvals pending in Switzerland and the U.K., and we're engaging with the European Union on resubmission. Again, we see an ex-U.S. market being very viable in the melanoma space. We have studies going on in frontline melanoma, which would about triple our potential in that space. Then, of course, everything for 2027, building off melanoma, does apply with the platform going into lung. We've released some data on lung recently, but also are preparing to file next year and enter the market in second line plus lung cancer, and that really is a huge opportunity for us. Also, I want to mention sarcoma trials are ongoing. We've released data recently on sarcoma, and we see opportunities there as well.
But again, the platform has been built, and we're growing it, so a lot of good things are happening.
Great. So yeah, you're scaling. The total addressable market in second-line melanoma, can you remind us how many patients that is per year? You just mentioned first line would be 3X. How about lung? How big is it compared to second-line melanoma?
Sure. If we look at it right now in the U.S. alone, second line plus metastatic melanoma, about 8,500 patients. We go 22,000 plus when we get into first line. If we look at the opportunities in other indications, in lung, we released data on non-squamous, and if we look at that market in non-squamous lung is 7X what we see the market potential in melanoma. If we look at actually the data showing KRAS wild-type, we saw biomarkers for KRAS wild-type, HER2 wild-type, ever smokers. That subset, where we saw about 60% efficacy in that patient population in the data released, that is 3X what we see in the melanoma market in second line plus. If we look at all of non-squamous at 7X, if we look at frontline plus second line, in KRAS wild-type is about 10 times.
It's a multi-billion dollar opportunity no matter how you look at it, and that's U.S. numbers. You can expand that as you look ex-U.S.
Before I forget, the sarcoma indications, the rare sarcomas, how big is that?
That opportunity there, because there really is nothing for those patients with it, that opportunity is equal to second-line plus metastatic melanoma.
Okay. Around 8,500 kind of thing.
You mentioned 80- Well, the patient population's lower, but the penetration's greater.
Oh, I see. Yes. Understood.
Going back to AMTAGVI for second-line melanoma, which is launching right now, you mentioned one of the priorities is these ATC sites, increasing. Anything else you are focused on to drive more growth?
Absolutely. Since I got here in February 2025, that is really where we started to see more and more penetration in the market with it, there has been three key areas of focus. The first one is looking at physician awareness. We have been able to raise, and I have talked about the very high numbers in treater awareness, but also too, we are focused on increasing referrer awareness. We see that growing in the surveys that we are having all the time and the efforts we are doing in the community space to get patients referred in earlier. That is the first area of focus. We talked about the ATCs, our authorized treatment centers for AMTAGVI. We continue to grow those. We had said we would open at least 110 by the end of the year, as we talked about in our earnings call a few weeks ago. We are well on track for that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
5 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
